Pharmaceuticals News

Installation phase will deploy NOMAD’s transportable battery energy storage technology at sites within Green Mountain Power’s service territory BOCA RATON, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) --...

Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones A patient treated with IMNN-001 will...

NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule...

RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related...

NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...

Blair, Nebraska, Aug. 26, 2026 (GLOBE NEWSWIRE) -- As the U.S. biotechnology sector grows, developing the skilled workforce needed to turn scientific innovation into products at commercial scale is...

FDA Fast Track Designation underscores the urgency of developing new treatment options and the potential of SOT106 to address a significant medical need.

Odyssey Therapeutics will participate in three upcoming global healthcare investor conferences this September, each featuring a fireside chat discussion.

- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with...